Therapy: Guidelines in rheumatology: Quo vadis?

Nature Reviews Rheumatology

Volumn 5, Issue 8, 2009, Pages 423-424

  Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

HUMAN; NOTE; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 73349090959     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.146     Document Type: Article

References (6)

1. Fautrel, B. et al. Choice of second-line disease modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clinical practice based on rheumatologists' preferences. Arthritis Care Res. 61, 425-434 (2009).
2. Solomon, D. H. & Kavanaugh, A. The economics of rheumatoid arthritis management. Int. J. Adv. Rheumatol. 6, 2-5 (2008).
3. Emery, P et al. Guidelines for initiation of anti- tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis. 68, 456-459 (2009).
4. Kavanaugh, A., Firestein, G. S. & Boyle, D. Biomarkers in rheumatology—pitfalls and promise. Future Rheumatology 3, 303-305 (2008).
5. Bellono, R. & Egi, M. What is a NICE-SUGAR for patients in the intensive care unit? Mayo Clin. Proc. 84, 400-402 (2009).
6. Harrington, J. T. Quality of care in rheumatic diseases: performance measures and improvement. Curr. Opin. Rheumatol. 20, 153-158 (2008).